Product
Agalsidase alfa
Aliases
Replagal®
2 clinical trials
1 indication
Indication
Fabry DiseaseClinical trial
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular HypertrophyStatus: Recruiting, Estimated PCD: 2025-12-29
Clinical trial
A Randomized, Open-label, Active Comparator, 2-arm, Prospective Study to Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry DiseaseStatus: Withdrawn, Estimated PCD: 2023-11-01